Source: Frontiers in Pharmacology. Unidade: IFSC
Subjects: DOENÇA DE CHAGAS, TRYPANOSOMA CRUZI, QUÍMICA MÉDICA, MODELAGEM MOLECULAR, PLANEJAMENTO DE FÁRMACOS
ABNT
PAULI, Ivani et al. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics. Frontiers in Pharmacology, v. 12, n. Ja 2022, p. 774069-1-774069-21 + supplementary material, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2021.774069. Acesso em: 18 nov. 2024.APA
Pauli, I., Rezende Junior, C. de O., Slafer, B. W., Dessoy, M. A., Souza, M. L. de, Ferreira, L. L. G., et al. (2022). Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics. Frontiers in Pharmacology, 12( Ja 2022), 774069-1-774069-21 + supplementary material. doi:10.3389/fphar.2021.774069NLM
Pauli I, Rezende Junior C de O, Slafer BW, Dessoy MA, Souza ML de, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Andricopulo RK, Duarte SM, Del Pintor RV, Silva FBR da, Cruz FC, Dias LC, Andricopulo AD. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics [Internet]. Frontiers in Pharmacology. 2022 ; 12( Ja 2022): 774069-1-774069-21 + supplementary material.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fphar.2021.774069Vancouver
Pauli I, Rezende Junior C de O, Slafer BW, Dessoy MA, Souza ML de, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Andricopulo RK, Duarte SM, Del Pintor RV, Silva FBR da, Cruz FC, Dias LC, Andricopulo AD. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics [Internet]. Frontiers in Pharmacology. 2022 ; 12( Ja 2022): 774069-1-774069-21 + supplementary material.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fphar.2021.774069